JCR Pharmaceuticals Co., Ltd.

Research JCR Pharmaceuticals Co., Ltd. (JCR) on Bullrun: valuation model: 16.6% overvalued, market cap EUR 300.16M, P/E 24.6, dividend yield 4.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerJCR
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryDrug Manufacturers - General
• CurrencyEUR
• Valuation signal16.6% overvalued
• Market capEUR 300.16M
• P/E24.6
• Dividend yield4.4%
• Financial periodFY2025
• RevenueEUR 33.07B
• Revenue growth-22.9%
• Net income-EUR 4.76B
• Free cash flow-EUR 15.37B
• Gross margin65.7%

Valuation Snapshot

Bullrun's latest valuation model marks JCR Pharmaceuticals Co., Ltd. as 16.6% overvalued; latest market cap is EUR 300.16M; P/E is 24.6; dividend yield is 4.4%.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease;

Frequently asked questions

Is JCR Pharmaceuticals Co., Ltd. overvalued or undervalued?

Bullrun's valuation model currently marks JCR Pharmaceuticals Co., Ltd. as 16.6% overvalued.

What is JCR Pharmaceuticals Co., Ltd.'s market cap?

JCR Pharmaceuticals Co., Ltd.'s market capitalization is EUR 300.16M.

What is JCR Pharmaceuticals Co., Ltd.'s P/E ratio?

JCR Pharmaceuticals Co., Ltd.'s price-to-earnings (P/E) ratio is 24.6.

Does JCR Pharmaceuticals Co., Ltd. pay a dividend?

JCR Pharmaceuticals Co., Ltd. has a dividend yield of 4.4%.

What does JCR Pharmaceuticals Co., Ltd. do?

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan.